13 Sep 2022
US sales boost margins
Creo Medical Group PLC develops and sells surgical devices for minimally invasive endoscopic surgery. These devices are used mainly to remove suspected early-stage bowel cancers including a recent surgical removal of a rare, complex gastrointestinal tumour. The devices are also now being used for p
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
US sales boost margins
Creo Medical Group Plc (CREO:LON) | 10.2 0 1.2% | Mkt Cap: 41.9m
- Published:
13 Sep 2022 -
Author:
Robin Davison | John Savin PhD | Daniel Appiah -
Pages:
6 -
Creo Medical Group PLC develops and sells surgical devices for minimally invasive endoscopic surgery. These devices are used mainly to remove suspected early-stage bowel cancers including a recent surgical removal of a rare, complex gastrointestinal tumour. The devices are also now being used for p